Conivaptan Interactions

Strong CYP3A4 inhibitor may increase systemic corticosteroid effects of fluticasone propionate.

Source: NLP:fluticasone propionate

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Source: NLP:suvorexant

Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Source: NLP:erlotinib

Strong CYP3A4 inhibitor that increases erlotinib exposure and risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Source: NLP:erlotinib hydrochloride

Strong CYP3A4 inhibitor that significantly increases nimodipine plasma concentration and blood pressure lowering effect. Concomitant administration should generally be avoided.

Source: NLP:nimodipine

CYP3A4 inhibitor that increases warfarin effect and INR; requires close monitoring.

Source: NLP:warfarin sodium

Deferasirox may induce CYP3A4 resulting in decreased conivaptan concentration. Monitor for reduced effectiveness.

Source: NLP:deferasirox

Increases digoxin serum concentration by 33% and AUC by 43%. Requires monitoring and dose adjustment.

Source: NLP:digoxin

Strong CYP3A inhibitor that increases paricalcitol exposure. Dose adjustment may be necessary; monitor iPTH and serum calcium.

Source: NLP:paricalcitol

Strong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse reactions, especially during first week of administration.

Source: NLP:rydapt